Fig 2.
Cumulative incidence of major adverse cardiovascular events among users of sodium glucose cotransporter 2 (SGLT2) inhibitors and matched users of dipeptidyl peptidase-4 (DPP-4) inhibitors in Ontario and Quebec, the two largest study sites
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.